Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul 3;2(7):e12069.
doi: 10.14814/phy2.12069. Print 2014 Jul 1.

Association of serum interleukin-27 with the exacerbation of chronic obstructive pulmonary disease

Takashi Angata  1 , Takeo Ishii  2 , Congxiao Gao  3 , Kazuaki Ohtsubo  3 , Shinobu Kitazume  3 , Akihiko Gemma  4 , Kozui Kida  2 , Naoyuki Taniguchi  3
Affiliations

Association of serum interleukin-27 with the exacerbation of chronic obstructive pulmonary disease

Takashi Angata et al. Physiol Rep. .

Abstract

We have previously demonstrated that chronic obstructive pulmonary disease (COPD) patients who do not have Siglec-14 are less prone to exacerbation of the disease. Siglec-14 is a myeloid cell protein that recognizes bacteria and triggers inflammatory responses. Therefore, soluble mediators secreted by myeloid cells responding to Siglec-14 engagement could be involved in the pathogenesis of exacerbation and could potentially be utilized as biomarkers of exacerbation. To find out, we sought genes specifically induced in Siglec-14(+) myeloid cells and evaluated their utility as biomarkers of COPD exacerbation. Using DNA microarray, we compared gene expression levels in Siglec-14(+) and control myeloid cell lines stimulated with or without nontypeable Haemophilus influenzae to select genes that were specifically induced in Siglec-14(+) cells. The expressions of several cytokine and chemokine genes were specifically induced in Siglec-14(+) cells. The concentrations of seven gene products were analyzed by multiplex bead array assays in paired COPD patient sera (n = 39) collected during exacerbation and stable disease states. Those gene products that increased during exacerbation were further tested using an independent set (n = 32) of paired patient sera. Serum concentration of interleukin-27 (IL-27) was elevated during exacerbation (discovery set: P = 0.0472; verification set: P = 0.0428; combined: P = 0.0104; one-sided Wilcoxon matched-pairs signed-rank test), particularly in exacerbations accompanied with sputum purulence and in exacerbations lasting more than a week. We concluded that IL-27 might be mechanistically involved in the exacerbation of COPD and could potentially serve as a systemic biomarker of exacerbation.

Keywords: Adaptive immunity; Siglec‐14; biomarkers; inflammation; innate immunity.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Changes of serum IL‐27, sICAM‐1, and C‐reactive protein (CRP) concentrations in association with exacerbation: stratification by the sputum purulence. The patient samples were stratified based on the presence (left column; n = 25) or absence (right column; n = 46) of sputum purulence during exacerbation. Each data point represents mean (x‐axis) and difference (y‐axis) of the analyte concentrations (pg/mL, represented in binary logarithm) in the paired patient sera collected during exacerbation and stable disease. Some data points (those that were above the quantifiable range) were omitted. Mean and 95% confidence intervals of y values are shown with solid and dotted lines, respectively.
Figure 2.
Figure 2.
Changes of serum IL‐27, sICAM‐1, and C‐reactive protein (CRP) concentrations in association with exacerbation: stratification by the time of sampling after the onset of exacerbation episode. The patient samples were stratified based on the timing of the blood sampling, which was either within the first week (left column, “Early phase”; n = 32) or after (right column, “Late phase”; n = 39) the onset of exacerbation. Each data point represents mean (x‐axis) and difference (y‐axis) of the analyte concentrations (pg/mL, represented in binary logarithm) in the paired patient sera collected during exacerbation and stable disease. Some data points (those that were above the quantifiable range) were omitted. Mean and 95% confidence intervals of y values are shown with solid and dotted lines, respectively.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Aaron S. D., Donaldson G. C., Whitmore G. A., Hurst J. R., Ramsay T., Wedzicha J. A. 2012. Time course and pattern of COPD exacerbation onset. Thorax; 67:238-243. - PubMed
    1. American Thoracic Society. 1995. Standardization of spirometry, 1994 update. Am. J. Respir. Crit. Care Med.; 152:1107-1136. - PubMed
    1. Andersson F., Borg S., Jansson S. A., Jonsson A. C., Ericsson A., Prutz C. 2002. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir. Med.; 96:700-708. - PubMed
    1. Angata T., Ishii T., Motegi T., Oka R., Taylor R. E., Soto P. C. 2013. Loss of Siglec‐14 reduces the risk of chronic obstructive pulmonary disease exacerbation. Cell. Mol. Life Sci.; 70:3199-3210. - PMC - PubMed
    1. Cao J., Zhang L., Li D., Xu F., Huang S., Xiang Y. 2012. IL‐27 is elevated in patients with COPD and patients with pulmonary TB and induces human bronchial epithelial cells to produce CXCL10. Chest; 141:121-130. - PMC - PubMed